0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Angiopoietin-like 3

Angiopoietin-like 3

Brief Information

Name:Angiopoietin like 3
Target Synonym:UNQ153/PRO179,Angiopoietin-5,Angiopoietin-like protein 3,Angiopoietin Like 3,Angiopoietin 5,ANGPT5,ANG-5,Angiopoietin-Related Protein 3,Angiopoietin-Like 3,FHBL2,ANL3,ANGPTL3
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

AN3-M52H3-ELISA
Mouse Angiopoietin-like 3, His TagMouse Angiopoietin-like 3, His Tag (Cat. No. AN3-M52H3) ELISA bioactivity

Immobilized Mouse Angiopoietin-like 3, His Tag (Cat. No. AN3-M52H3) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human ANGPTL3 Antibody, Human IgG1 with a linear range of 0.1-1 ng/mL (QC tested).

AN3-H52H3-ELISA
Human Angiopoietin-like 3, His TagHuman Angiopoietin-like 3, His Tag (Cat. No. AN3-H52H3) ELISA bioactivity

Immobilized Human Angiopoietin-like 3, His Tag (Cat. No. AN3-H52H3) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human ANGPTL3 Antibody, Human IgG1 with a linear range of 0.5-2 ng/mL (QC tested).

Synonym Name

ANGPTL3,ANGPT5,ANG-5,Angiopoietin-5,FHBL2

Background

Angiopoietin-like protein 3 (ANGPTL3) is also known as Angiopoietin-related protein 3, Angiopoietin-5 (ANGPT5 / ANG-5), is a member of the angiopoietin-like family of secreted factors. ANGPTL3 / ANGPT5 is predominantly expressed in the liver, and has the characteristic structure of angiopoietins, consisting of a signal peptide, N-terminal coiled-coil domain and the C-terminal fibrinogen (FBN)-like domain. The FBN-like domain in angiopoietin-like 3 protein was shown to bind alpha-5/beta-3 integrins, and this binding induced endothelial cell adhesion and migration. This protein may also play a role in the regulation of angiogenesis. Angptl3 also acts as dual inhibitor of lipoprotein lipase (LPL) and endothelial lipase (EL), and increases plasma triglyceride and HDL cholesterol in rodents. ANGPTL3 inhibit endothelial lipase to catalyze HDL-phospholipid and increase HDL-PL levels. Circulating PL-riched HDL particles have high cholesterol efflux abilities.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Evinacumab REGN-1500 Approved Regeneron Pharmaceuticals Inc Evkeeza EU Hypercholesterolemia Regeneron Ireland Designated Activity Company 2021-02-11 Homozygous familial hypercholesterolemia; Hypertriglyceridemia; Hypercholesterolemia; Metabolic Diseases Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
IONIS-ANGPTL3Rx ISIS-703802; PF-07285557 Phase 2 Clinical Ionis Pharmaceuticals Inc Hypertriglyceridemia; Homozygous familial hypercholesterolemia; Non-alcoholic Fatty Liver Disease; Diabetes Mellitus, Type 2; Hyperlipoproteinaemia type IIa; Hyperlipoproteinemia Type I; Hyperlipoproteinemias; Dyslipidemias; Cardiovascular Diseases; Hyperlipoproteinemia Type II; Hyperlipidemias Details
ARO-ANG3 ARO-ANG3 Phase 2 Clinical Arrowhead Pharmaceuticals Hypertriglyceridemia; Dyslipidemias; Hyperlipoproteinemia Type II; Lipid Metabolism Disorders Details
ARO-APOC3 ARO-APOC3 Phase 2 Clinical Arrowhead Pharmaceuticals Hypertriglyceridemia Details

This web search service is supported by Google Inc.

totop